Baseline demographic and clinical characteristics
| Overall (N=2299) | ICI (N=605) | Chemo (N=1092) | ICI+chemo (N=602) | |
| Demographic characteristics | ||||
| Median age at index (IQR), years | 62 (58–69) | 64 (58–73) | 62 (58–68) | 62 (57–68) |
| Male, n (%) | 1274 (55.4) | 326 (53.9) | 633 (58.0) | 315 (52.3) |
| Baseline BMI, median | 25.7 | 25.7 | 25.8 | 25.7 |
| Insurance type, % | ||||
| Commercial | 1627 (70.8) | 380 (62.8) | 802 (73.4) | 445 (73.9) |
| Medicare Advantage | 672 (29.2) | 225 (37.2) | 290 (26.6) | 157 (26.1) |
| Cancer treatment history during the 12-month baseline period, n (%) | ||||
| Surgery | 321 (14.0) | 78 (12.9) | 166 (15.2) | 77 (12.8) |
| Radiation therapy | 960 (41.8) | 283 (46.8) | 468 (42.9) | 209 (34.7) |
| ICIs | 80 (3.5) | 36 (6.0) | 28 (2.6) | 16 (2.7) |
| Chemotherapy | 353 (15.4) | 161 (26.6) | 149 (13.6) | 43 (7.1) |
| Targeted therapy | 77 (3.3) | 31 (5.1) | 38 (3.5) | ≤10 (NA) |
| Clinical characteristics | ||||
| Modified DCCI* at baseline, median (range) | 2 (1–3) | 2 (1–3) | 2 (1–3) | 1 (1–3) |
| Baseline individual DCCI comorbidities,† n (%) | ||||
| CHF | 267 (11.6) | 72 (11.9) | 135 (12.4) | 60 (10.0) |
| Diabetes with chronic complication | 162 (7.0) | 45 (7.4) | 78 (7.1) | 39 (6.5) |
| MI | 183 (8.0) | 55 (9.1) | 87 (8.0) | 41 (6.8) |
| Renal disease | 188 (8.2) | 65 (10.7) | 82 (7.5) | 41 (6.8) |
| Cerebrovascular disease | 358 (15.6) | 105 (17.4) | 168 (15.4) | 85 (14.1) |
| Chronic pulmonary disease | 1498 (65.2) | 393 (65.0) | 710 (65.0) | 395 (65.6) |
| Atrial fibrillation | 239 (10.4) | 79 (13.1) | 109 (10.0) | 51 (8.5) |
| Baseline other comorbidities, n (%) | ||||
| Hypertension | 1434 (62.4) | 388 (64.1) | 675 (61.8) | 371 (61.6) |
| CVC or PICC | 826 (35.9) | 139 (23.0) | 433 (39.7) | 254 (42.2) |
| Obesity | 319 (13.9) | 78 (12.9) | 150 (13.7) | 91 (15.1) |
| Bleeding | 320 (13.9) | 88 (14.5) | 145 (13.3) | 87 (14.5) |
| Baseline ECOG PS at baseline, n (%) | ||||
| 0 | 739 (32.1) | 192 (31.7) | 342 (31.3) | 205 (34.1) |
| 1 | 1189 (51.7) | 311 (51.4) | 556 (50.9) | 322 (53.5) |
| 2 | 186 (8.1) | 70 (11.6) | 74 (6.8) | 42 (7.0) |
| 3 | 16 (0.7) | ≤10 (NA) | 13 (1.2) | ≤10 (NA) |
| Khorana risk score | ||||
| Patients with baseline Khorana risk score, n (%) | 472 (21) | 112 (19) | 227 (21) | 133 (22) |
| Patients’ baseline characteristics for Khorana risk score calculation, n (%) | ||||
| Platelet count ≥350×10⁹/L | 166 (35.2) | 46 (41.1) | 59 (26.0) | 61 (45.9) |
| Hemoglobin level <10 g/dL | 36 (7.6) | ≤10 (NA) | 19 (8.4) | ≤10 (NA) |
| Leukocyte count >11×10⁹/L | 106 (22.5) | 26 (23.2) | 50 (22.0) | 30 (22.6) |
| BMI ≥35 kg/m² | 181 (38.3) | 54 (48.2) | 77 (33.9) | 50 (37.6) |
| Baseline Khorana risk score, n (%) | ||||
| 1, low risk for VTE | 260 (55.1) | 58 (51.8) | 132 (58.1) | 70 (52.6) |
| ≥2, high risk for VTE | 212 (44.9) | 54 (48.2) | 95 (41.9) | 63 (47.4) |
*An index that assigns a score to various chronic medical conditions and uses the sum to predict long-term mortality.33 34
†These are select DCCI comorbidities. The full complement of DCCI comorbidities are AIDS, any malignancy, cerebrovascular disease, chronic pulmonary disease, CHF, dementia, diabetes without complications, diabetes without chronic complications, hemiplegia or paraplegia, metastatic solid tumor, mild liver disease, moderate/severe liver disease, MI, peptic ulcer disease, peripheral vascular disease, renal disease, rheumatoid disease.33 34
AIDS, acquired immune deficiency syndrome; BMI, body mass index; CHF, congestive heart failure; CVC, central venous catheter; DCCI, Deyo-Charlson Comorbidity Index; ECOG PS, Eastern Cooperative Oncology Group performance status; ICI, immune checkpoint inhibitor; IQR, interquartile range; MI, myocardial infarction; NA, not applicable; PICC, peripherally inserted central catheter; VTE, venous thromboembolism.